Registration is full for this event.
Save the Date: CORD's Fall Conference launches November 6 - 7, 2017 at the Hyatt Regency Toronto
Health Canada Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: Toronto, ON – May 12, 2016
Join us and become part of an active Canadian rare disorder community. The only national organization representing all rare disorder patient groups in Canada.